De novo lipogenesis (DNL) is the metabolic pathway converting excess carbohydrate-derived acetyl-CoA into saturated fatty acids, primarily palmitate (16:0). This process occurs predominantly in hepatocytes and adipocytes under conditions of carbohydrate surplus and high insulin signaling. DNL contributes approximately 25% of hepatic triglyceride accumulation in NAFLD, with chronic activation representing a key metabolic mismatch in modern carbohydrate-rich diets.
Think of DNL as a factory assembly line that only turns on when the warehouse is overstocked with raw materials. When glucose shipments exceed what the cell can immediately use or store as glycogen (the warehouse is full), the factory manager (insulin) activates a backup production line. Glucose gets broken down in the loading dock (mitochondria) into acetyl-CoA units β small two-carbon building blocks. These blocks are shuttled out to the factory floor (cytoplasm) as citrate, then reassembled by two key machines: ACC (the starter machine that makes the first committed step, producing malonyl-CoA) and FAS (the assembly conveyor that chains together 8 malonyl-CoA units to build a 16-carbon palmitate). The problem: this assembly line was designed for occasional use during harvest season, but in modern life it runs continuously. The factory produces so much fat that it gets stored in places it shouldn't β like the liver warehouse itself, clogging the machinery and triggering inflammation. Meanwhile, in a ketogenic or fasted state, the factory shuts down because acetyl-CoA gets diverted to a different emergency power generator (ketogenesis) instead.
DNL occurs in a multi-step cytoplasmic pathway regulated at transcriptional, allosteric, and hormonal levels:
Step 1: Substrate Generation (Mitochondrial)
- Excess glucose β glycolysis β pyruvate β mitochondrial acetyl-CoA
- Fructose bypasses phosphofructokinase regulation, entering glycolysis as dihydroxyacetone phosphate and glyceraldehyde-3-phosphate, generating acetyl-CoA more directly
- Alcohol (ethanol) β acetate β acetyl-CoA (bypassing glycolytic regulation entirely)
Step 2: Citrate Shuttle
- Mitochondrial acetyl-CoA + oxaloacetate β citrate (via citrate synthase)
- Citrate exported to cytoplasm via citrate-malate antiporter
- Cytoplasmic ATP citrate lyase (ACLY) cleaves citrate back to acetyl-CoA + oxaloacetate
Step 3: Committed Step
- Acetyl-CoA carboxylase (ACC1 in cytoplasm, ACC2 at mitochondrial membrane) converts acetyl-CoA β malonyl-CoA
- This is the rate-limiting, irreversible step
- ACC is activated by: insulin (via Akt-mediated dephosphorylation), citrate (allosteric)
- ACC is inhibited by: AMPK phosphorylation (energy deficit), glucagon, long-chain fatty acyl-CoAs
Step 4: Fatty Acid Synthesis
- Fatty acid synthase (FAS) complex uses 1 acetyl-CoA (primer) + 7 malonyl-CoA units
- Repetitive cycle: condensation β reduction β dehydration β reduction
- Produces palmitate (16:0) after 7 cycles
- Requires NADPH (from pentose phosphate pathway and malic enzyme)
Step 5: Elongation and Desaturation
- Palmitate β stearate (18:0) via ELOVL6
- Stearate β oleate (18:1n-9) via SCD1 (stearoyl-CoA desaturase-1)
- Triglyceride assembly via GPAT, AGPAT, DGAT enzymes
- VLDL packaging and secretion (ApoB100, MTP-mediated)
Transcriptional Regulation
- Insulin β Akt β mTORC1 β SREBP-1c (sterol regulatory element-binding protein-1c) activation
- SREBP-1c translocates to nucleus, upregulates ACC, FAS, SCD1, GPAT
- ChREBP (carbohydrate response element-binding protein) activated by high glucose, xylulose-5-phosphate
- PPARΞ± (activated in fasting/ketosis) suppresses SREBP-1c
- FGF21 (fasting/ketogenic state) suppresses ChREBP
Ketogenic State Competition
- In fasting or carbohydrate restriction, hepatic acetyl-CoA diverts to ketogenesis
- Low insulin β AMPK activation β ACC phosphorylation/inhibition
- Reduced malonyl-CoA relieves inhibition of CPT1A β fatty acid oxidation increases
- Acetyl-CoA β HMGCS2 β Ξ²-hydroxybutyrate and acetoacetate
- This metabolic switch is mutually exclusive: high DNL = low ketogenesis, and vice versa
graph TD
A[Excess Glucose/Fructose] --> B[Pyruvate]
B --> C[Mitochondrial Acetyl-CoA]
C --> D[Citrate]
D --> E[Cytoplasmic Acetyl-CoA]
E --> F["ACC: Acetyl-CoA β Malonyl-CoA"]
F --> G["FAS: 7 Malonyl-CoA + 1 Acetyl-CoA"]
G --> H["Palmitate 16:0"]
H --> I["Stearate 18:0"]
I --> J["Oleate 18:1"]
J --> K[Triglyceride Assembly]
K --> L[VLDL Secretion]
M[Insulin] --> N[Akt/mTORC1]
N --> O[SREBP-1c Activation]
O --> F
P[AMPK Activation] -.Inhibits.-> F
Q[Glucagon/Fasting] -.Inhibits.-> F
R[Fasting State] --> S["Acetyl-CoA β Ketogenesis"]
S -.Competes with.-> C
style F fill:#ff9999
style M fill:#99ccff
style P fill:#ffcc99
Primary Clinical Relevance
DNL is central to understanding and treating NAFLD/NASH, metabolic syndrome, Type 2 Diabetes, and insulin resistance. In affluent populations with continuous access to refined carbohydrates, DNL runs chronically rather than episodically, creating an evolutionary mismatch. The hunter-gatherer phenotype evolved DNL for seasonal carbohydrate abundance (honey, fruit in late summer/autumn), converting excess to fat for winter survival. In modern contexts, this system malfunctions under constant activation.
Selfish Brain and Liver Conflict
The selfish brain prioritizes glucose delivery, but chronic hyperglycemia triggers hepatic DNL as a protective overflow mechanism. However, this "protection" becomes pathological: hepatic steatosis β ER stress β inflammasome activation (NLRP3 inflammasome) β NASH progression β fibrosis β cirrhosis β hepatocellular carcinoma. The liver's attempt to manage glucose excess becomes self-destructive.
Specific Clinical Thresholds
- DNL contributes ~25% of hepatic triglycerides in NAFLD (adipose lipolysis ~60%, dietary fat ~15%)
- DNL flux increases 3-5 fold in NAFLD patients vs. healthy controls
- Fasting serum triglycerides >150 mg/dL suggest elevated hepatic DNL
- Elevated VLDL-triglyceride and VLDL-particle number indicate active hepatic lipogenesis
- Hepatic steatosis threshold: >5% liver fat by MRI-PDFF
Intervention Strategies
- Dietary carbohydrate restriction β reduces DNL substrate availability; particularly effective for fructose restriction (no soft drinks, fruit juice, HFCS)
- ketogenic diet β shifts acetyl-CoA partitioning away from DNL toward ketogenesis; activates PPARΞ± and inhibits SREBP-1c
- time-restricted eating / Intermittent fasting β creates daily fasting windows where insulin drops, AMPK activates, ACC is inhibited
- Exercise β activates AMPK, increases fatty acid oxidation, reduces mTORC1 activation
- Pharmacological ACC inhibitors (e.g., firsocostat) β in clinical trials for NASH, directly block the rate-limiting step
Biomarker Assessment
- Measure DNL indirectly via: fasting insulin, HOMA-IR, triglyceride/HDL ratio, VLDL particle number
- Advanced: hepatic MRI-PDFF for steatosis quantification
- Research setting: deuterated water incorporation into palmitate (direct DNL measurement)
Metamodel Integration
- Metamodel 1 (Chronic inflammation): DNL-derived saturated fats activate TLR4 signaling β hepatic inflammation
- Metamodel 3 (Selfish systems): Liver prioritizes glucose disposal over systemic metabolic health
- Metamodel 5 (Evolutionary mismatch): DNL adapted for intermittent carbohydrate excess, fails under chronic activation
- De novo lipogenesis converts excess carbohydrate-derived acetyl-CoA into palmitate (16:0 saturated fatty acid)
- Occurs primarily in liver (hepatocytes) and adipose tissue; minimal in muscle
- Rate-limiting enzyme: ACC (acetyl-CoA carboxylase), produces malonyl-CoA (committed step)
- Key synthetic enzyme: FAS (fatty acid synthase), assembles 8 acetyl units into palmitate
- Activated by: insulin (via Akt/mTORC1/SREBP-1c), high carbohydrate intake (ChREBP), citrate (allosteric)
- Inhibited by: AMPK phosphorylation, glucagon, long-chain fatty acids, PPARΞ± activation
- Fructose is uniquely lipogenic: bypasses phosphofructokinase regulation, enters glycolysis downstream, saturates glycogen stores rapidly, drives DNL more than glucose
- Contributes ~25% of liver fat in NAFLD (rest from adipose lipolysis ~60%, dietary fat ~15%)
- Chronic DNL elevation increases: hepatic triglycerides, VLDL secretion, plasma triglycerides, small dense LDL particles
- Metabolic competition: acetyl-CoA partitioning between DNL (fed state) and ketogenesis (fasted state) is mutually exclusive
- Ketogenic diet shifts acetyl-CoA β ketone bodies, suppresses DNL via PPARΞ± activation and SREBP-1c inhibition
- DNL requires NADPH from pentose phosphate pathway (glucose-6-phosphate dehydrogenase) and malic enzyme
- Normal DNL flux: ~1-3% of carbohydrate intake; in NAFLD: 5-10% or higher
- Pharmacological targets: ACC inhibitors (firsocostat), DGAT inhibitors, SCD1 inhibitors (in development for NASH)
- NAFLD β DNL is a primary driver of hepatic steatosis, contributing 25% of liver fat accumulation in non-alcoholic fatty liver disease
- NASH β chronic DNL activation produces lipotoxic saturated fatty acids (palmitate) that trigger ER stress, inflammasome activation, and hepatocyte apoptosis
- Insulin β insulin activates DNL via Akt β mTORC1 β SREBP-1c transcriptional cascade; hyperinsulinemia drives chronic lipogenesis
- insulin resistance β DNL-derived saturated fats activate TLR4 and PKCΞ΅, impairing insulin receptor signaling in liver and muscle
- mTORC1 β mechanistic target of rapamycin complex 1 mediates insulin's activation of SREBP-1c and upregulation of lipogenic enzymes
- SREBP-1c β master transcription factor for DNL genes (ACC, FAS, SCD1); insulin-responsive via mTORC1
- Acetyl-CoA β central substrate for DNL; metabolic competition exists between DNL and ketogenesis for acetyl-CoA
- hepatic ketogenesis β alternative fate for acetyl-CoA in fasted/ketogenic states; suppressed when DNL is active
- HMGCS2 β mitochondrial enzyme initiating ketogenesis, competes with DNL for acetyl-CoA in fasting states
- Ξ²-hydroxybutyrate β primary ketone body produced when acetyl-CoA diverts away from DNL; suppresses NLRP3 inflammasome
- PPARΞ± β peroxisome proliferator-activated receptor alpha; activated by fasting, ketones, omega-3s; suppresses SREBP-1c and DNL
- ketogenic diet β dietary intervention that suppresses DNL by reducing insulin, activating AMPK, shifting acetyl-CoA to ketogenesis
- Fructose β highly lipogenic monosaccharide; bypasses glycolytic regulation, rapidly saturates glycogen stores, drives DNL more than glucose
- metabolic syndrome β DNL elevation is characteristic; contributes to hypertriglyceridemia, low HDL, visceral adiposity, insulin resistance
- Type 2 Diabetes β chronic DNL contributes to hepatic insulin resistance and gluconeogenesis dysregulation
- time-restricted eating β creates daily fasting windows where insulin drops, AMPK activates, ACC is inhibited, DNL suppressed
- Intermittent fasting β extends fasting periods, promotes fatty acid oxidation over synthesis, shifts metabolism away from DNL
- NLRP3 inflammasome β activated by DNL-derived saturated fatty acids (palmitate) and ER stress in hepatocytes, driving NASH progression
- ER stress β endoplasmic reticulum stress induced by excess lipid synthesis overwhelms folding capacity, triggers UPR and apoptosis
- Fatty acid β palmitate (16:0) is the primary product of DNL; elongated to stearate (18:0), desaturated to oleate (18:1)
- fatty acid oxidation β suppressed when DNL is active via malonyl-CoA inhibition of CPT1A; restored in fasting/ketogenic states
- VLDL β very low-density lipoprotein particles secreted by liver to export DNL-derived triglycerides; elevated in NAFLD
- hypertriglyceridemia β plasma triglyceride elevation driven by hepatic VLDL overproduction from active DNL
- visceral adipose tissue β also performs DNL; adipocyte lipogenesis contributes to visceral fat accumulation in metabolic syndrome
- gut microbiome β short-chain fatty acids (acetate, propionate) can serve as DNL substrates; dysbiosis may influence hepatic lipogenesis